Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?
Yıl: 2020 Cilt: 7 Sayı: 4 Sayfa Aralığı: 271 - 275 Metin Dili: İngilizce DOI: 10.4274/jus.galenos.2020.3342 İndeks Tarihi: 30-04-2021
Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?
Öz: Objective: Non-muscle invasive bladder cancer (NMIBC) accounts for 75% of all bladder cancer cases. Several models to predict relapses and progression have been developed. We aimed to determine the predictive value of the neutrophil-lymphocyte ratio (NLR) for recurrence and/or progression of the disease.Materials and Methods: Seventy patients with high-risk NMIBC according to the European Organization for Research and Treatment of Cancer (EORTC) risk classification who were receiving Bacillus Calmette-Guerin (BCG) treatment and were followed up at our clinic were included in the study.Results: The average score level and NLR values differed significantly on patient classification according to the EORTC Progression and Recurrence Risk score. The positive correlations among EORTC Recurrence score, EORTC Progression score, Club Urológico Espanol de Tratamiento Oncológico (CUETO) Recurrence score, and CUETO Progression score and NLR values were not statistically significant. The NLR values decreased significantly on follow-ups on BCG treatment.Conclusion: Patients with bladder cancer have a high NLR, which has predictive utility with regard to prognosis. A decrease in NLR with BCG treatment is indicative of the decreased likelihood of recurrence and progression.
Anahtar Kelime: BCG Tedavisi ile Nötrofil-lenfosit Oranındaki Azalma NMIBC için Prognostik Bir Belirteç Olabilir Mi?
Öz: Amaç: Kas invazif olmayan mesane kanserleri, tüm mesane kanserlerinin %75’ini oluşturmaktadır. Relaps and progresyonu tahmin etmek için bir çok model geliştirilmiştir. European Organization for Research and Treatment of Cancer (EORTC) risk sınıflandırmasına göre yüksek risk kategorisinde olup Bacillus Calmette-Guerin (BCG) tedavisi başlanmış ve 1 yıllık BCG tedavisinde nüks ve progresyon gözlenmemiş hastalar retrospektif olarak analiz edildi. Bu durumu tahmin edebilecek nötrofil/lenfosit oranları (NLR) araştırıldı. Gereç ve Yöntem: EORTC risk sınıflandırmasına göre yüksek risk grubunda BCG tedavisi başlatılan ve kliniğimizde takip edilen 70 hasta çalışmaya dahil edildi. Bulgular: EORTC Progresyon ve Rekürrens Risk Skoru Sınıflamasına göre skor seviyesi ve NLR değerlerinin ortalaması istatistiksel olarak farklı bulundu. EORTC Rekürrens skoru, EORTC İlerleme skoru, Club Urológico Espanol de Tratamiento Oncológico (CUETO) Rekürrens skoru ve CUETO Progresyon skoru artışı ve NLR değerleri arasında yapılan korelasyon analizinde istatistiksel olarak anlamlı bir sonuç saptanmadı. BCG tedavisi ile birlikte takiplerde NLR değerleri önemli ölçüde azaldı. Sonuç: NLR değeri mesane kanseri ile ilişkili olarak artmakta ve progresyon ve rekürrens tahmini için bir prognoz parametresi olarak kullanılabilir. BCG tedavisi ile birlikte değerinde düşme olması rekürrens ve progresyon olmamasının bir göstergesi olabilir
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Babjuk M, Burger M, Compérat E, Gontero P, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Sylvester R, Zigeuner R. Non-muscle-invasive Bladder Cancer. https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/#note_8 (available date 18/12/2019)
- 2. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, Dandona L, Fleming T, Forouzanfar MH, Hancock J, Hay RJ, Hunter-Merrill R, Huynh C, Hosgood HD, Johnson CO, Jonas JB, Khubchandani J, Kumar GA, Kutz M, Lan Q, Larson HJ, Liang X, Lim SS, Lopez AD, MacIntyre MF, Marczak L, Marquez N, Mokdad AH, Pinho C, Pourmalek F, Salomon JA, Sanabria JR, Sandar LL, Sartorius B, Schwartz SM, Shackelford KA, Shibuya K, Stanaway J, Steiner C, Sun J, Takahashi K, Vollset SE, Vos T, Wagner JA, Wang H, Westerman R, Zeeb H, Zoeckler L, Abd-Allah F, Ahmed MB, Alabed S, Alam NK, Aldhahri SF, Alem G, Alemayohu MA, Ali R, Al-Raddadi R, Amare A, Amoako Y, Artaman A, Asayesh H, Atnafu N, Awasthi A, Saleem HB, Barac A, Bedi N, Bensenor I, Berhane A, Bernabé E, Betsu B, Binagwaho A, Boneya D, Campos-Nonato I, Castañeda-Orjuela C, Catalá-López F, Chiang P, Chibueze C, Chitheer A, Choi AJ, Cowie B, Damtew S, das Neves J, Dey S, Dharmaratne S, Dhillon P, Ding E, Driscoll T, Ekwueme D, Endries AY, Farvid M, Farzadfar F, Fernandes J, Fischer J, G/Hiwot T, Gebru A, Gopalani S, Hailu A, Horino M, Horita N, Husseini A, Huybrechts I, Inoue M, Islami F, Jakovljevic M, James S, Javanbakht M, Ha Jee S, Kasaeian A, Kedir MS, Khader YS, Khang YH, Kim D, Leigh J, Linn S, Lunevicius R, Abd El Razek HM, Malekzadeh R, Malta DC, Marcenes W, Markos D, Melaku YA, Meles KG, Mendoza W, Mengiste DT, Meretoja TJ, Miller TR, Mohammad KA, Mohammadi A, Mohammed S, Moradi-Lakeh M, Nagel G, Nand D, Le Nguyen Q, Nolte S, Ogbo FA, Oladimeji KE, Oren E, Pa M, Park EK, Pereira DM, Plass D, Qorbani M, Radfar A, Rafay A, Rahman M, Rana SM, Søreide K, Satpathy M, Sawhney M, Sepanlou SG, Shaikh MA, She J, Shiue I, Shore HR, Shrime G, So S, Soneji S, Stathopoulou V, Stroumpoulis K, Sufiyan MB, Sykes BL, Tabarés-Seisdedos R, Tadese F, Tedla BA, Tessema GA, Thakur JS, Tran BX, Ukwaja KN, Uzochukwu BSC, Vlassov VV, Weiderpass E, Terefe MW, Yebyo HG, Yimam HH, Yonemoto N, Younis MZ, Yu C, Zaidi Z, El Sayed Zaki M, Zenebe ZZ, Murray CJL, Naghavi M. Global, regional, and national cancer ıncidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 2017;3:524-548.
- 3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and majör patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386.
- 4. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CancerJ Clin 2014;64:9-29.
- 5. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol 2017;71:96-108.
- 6. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M; European Association of Urology. EAU guidelines on non–muscle-invasive Urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64:639-653.
- 7. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y. Epidemiology and risk factors of urothelialbladder cancer. Eur Urol 2013;63:234-241.
- 8. Getzler I, Bahouth Z, Nativ O, Rubinstein J, Halachmi S. Preoperative neutrophil to lymphocyte ratio improves recurrence prediction of non-muscle invasive bladder cancer. BMC Urol 2018;18:90.
- 9. Hirahara T, Arigami T, Yanagita S, Matsushita D, Uchikado Y, Kita Y, Mori S, Sasaki K, Omoto I, Kurahara H, Maemura K, Okubo K, Uenosono Y, Ishigami S, Natsugoe S. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer 2019;19:672.
- 10. Huang H, Wan X, Bai Y, Bian J, Xiong J, Xu Y, Sang X, Zhao H. Preoperative neutrophil–lymphocyte and platelet– lymphocyte ratios as independent predictors of T stages in hilar cholangiocarcinoma. Cancer Manag Res 2019;11:5157-5162.
- 11. Ceylan C, Doluoglu OG, Keleş I, Gazel E, Temucin T, Odabaş O, Karalar M. Importance of the neutrophil-to-lymphocyte ratio in muscle-invasive and non-muscle invasive bladder tumors. Urologia 2014;81:120-124.
- 12. Marchioni M, Primiceri G, Ingrosso M, Filograna R, Castellan P, De Francesco P, Schips L. The clinical use of the neutrophil to lymphocyte ratio (NLR) in urothelial cancer: a systematic review. Clin Genitourin Cancer 2016;14:473-484.
- 13. Paramanathan A, Saxena A, Morris DL. A systematic review and meta-analysis on the impact of preoperative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol 2014;23:31-39.
- 14. Mano R, Baniel J, Shoshany O, Margel D, Bar-On T, Nativ O, Rubinstein J, Halachmi S. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer. Urol Oncol 2015;33:67.e1-7
- 15. Racioppi M, Di Gianfrancesco L, Ragonese M, Palermo G, Sacco E, Bassi PF. Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer? Int Braz J Urol 2019;45:315-324.
- 16. Yuk HD, Jeong CW, Kwak C, Kim HH, Ku JH. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in non-muscle ınvasive bladder cancer patients: ınitial ıntravesical Bacillus Calmette-Guerin treatment after transurethral resection of bladder tumor setting. Front Oncol 2019;17;8:642.
- 17. Favilla V, Castelli T, Urzi D, Reale G, Privitera S, Salici A, Russo GI, Cimino S, Morgia G. Neutrophil to lymphocyte ratio, a biomarker in non-muscle invasive bladder cancer: a single-institutional longitudinal study. Int Braz J Urol 2016;42:685-693.
- 18. D’Andrea D, Moschini M, Gust K, Abufaraj M, Ozsoy M, Mathieu R, Soria F, Briganti A, Rouprêt M, Karakiewicz PI, Shariat SF. Prognostic role of neutrophil-to- lymphocyte ratio in primary non-muscle-invasive bladder cancer. Clin Genitourin Cancer 2017;15:e755-e764.
- 19. Çelen S, Günseren KÖ, Özlülerden Y, Mete A, Tuncay ÖL, Yavaşcaoğlu İ. Does neutrophil-lymphocyte ratio show recurrence in patients who underwent curative resection for non-muscle-invasive bladder cancer? J Surg Med 2019;3:324-327.
- 20. Aydın M, Bitkin A, Kadıhasanoğlu M, İrkılata L, Akgüneş E, Keleş M, Atilla MK. Correlation of neutrophil-lymphocyte ratio and risk scores in non-muscle invasive bladder cancer. Actas Urol Esp 2019;43:503-508.
- 21. Kaynar M, Goktas S. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer. Urol Oncol 2015;33:497.
- 22. Cimen HI, Halis F, Saglam HS, Gokce A. Can neutrophil to lymphocyte ratio predict lamina propria invasion in patients with non-muscle invasive bladder cancer? Int Braz J Urol 2017;43:67-72.
| APA | baser a (2020). Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?. , 271 - 275. 10.4274/jus.galenos.2020.3342 |
| Chicago | baser aykut Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?. (2020): 271 - 275. 10.4274/jus.galenos.2020.3342 |
| MLA | baser aykut Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?. , 2020, ss.271 - 275. 10.4274/jus.galenos.2020.3342 |
| AMA | baser a Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?. . 2020; 271 - 275. 10.4274/jus.galenos.2020.3342 |
| Vancouver | baser a Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?. . 2020; 271 - 275. 10.4274/jus.galenos.2020.3342 |
| IEEE | baser a "Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?." , ss.271 - 275, 2020. 10.4274/jus.galenos.2020.3342 |
| ISNAD | baser, aykut. "Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?". (2020), 271-275. https://doi.org/10.4274/jus.galenos.2020.3342 |
| APA | baser a (2020). Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?. Journal of Urological Surgery, 7(4), 271 - 275. 10.4274/jus.galenos.2020.3342 |
| Chicago | baser aykut Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?. Journal of Urological Surgery 7, no.4 (2020): 271 - 275. 10.4274/jus.galenos.2020.3342 |
| MLA | baser aykut Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?. Journal of Urological Surgery, vol.7, no.4, 2020, ss.271 - 275. 10.4274/jus.galenos.2020.3342 |
| AMA | baser a Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?. Journal of Urological Surgery. 2020; 7(4): 271 - 275. 10.4274/jus.galenos.2020.3342 |
| Vancouver | baser a Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?. Journal of Urological Surgery. 2020; 7(4): 271 - 275. 10.4274/jus.galenos.2020.3342 |
| IEEE | baser a "Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?." Journal of Urological Surgery, 7, ss.271 - 275, 2020. 10.4274/jus.galenos.2020.3342 |
| ISNAD | baser, aykut. "Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?". Journal of Urological Surgery 7/4 (2020), 271-275. https://doi.org/10.4274/jus.galenos.2020.3342 |
